Skip to content
Nobel Jews
Portrait of Michael S. Brown
Photo: The original uploader was Rrawson at English Wikipedia., Transferred from en.wikipedia to Commons by Maniago. · CC BY-SA 3.0 via Wikimedia Commons

Nobel Prize in Physiology or Medicine · 1985

Michael S. Brown

With Joseph Goldstein he found the LDL receptor, showing how cells pull cholesterol from the blood and how statins protect hearts.

The Nobel citation: “for their discoveries concerning the regulation of cholesterol metabolism”
Born
April 13, 1941, New York, NY, USA
Affiliation at the time
University of Texas Southwestern Medical Center at Dallas, USA

Medicine prize

1985

Shared with 1 other laureate.

Age that year

44years

Born in 1941.

Headline credited impact

85,000–240,000lives saved

Deaths prevented or postponed by statin therapy worldwide (1987-2025). How it was built

Sources cited

24

Fact-checked September 24, 2026.

  • He traces his interest in science to age 13, when he got an amateur radio license and built transmitters that often blew all the fuses in the house.
  • At the University of Pennsylvania he majored in chemistry but spent most of his time at the student paper, as features editor and briefly editor-in-chief.
  • His Nobel work was spurred by two siblings, aged 6 and 8, who kept having heart attacks because their LDL cholesterol was eight times normal.
  • In 1981, months after Merck halted its statin trials over a cancer scare, he and Goldstein showed in dogs that the drug boosted liver LDL receptors and lowered LDL.
  • He met Joseph Goldstein as a young doctor in Boston in 1966; they merged their Dallas labs by 1974 and were still publishing together four decades later.

The breakthrough

The LDL receptor and how cells control their cholesterol (1972-1985)

Cholesterol is not simply a villain. Every cell needs it to build its outer skin, and the body turns it into hormones and bile. Because cholesterol does not dissolve in water, blood carries it inside tiny fat-and-protein packages called LDL. In 1972 Brown and his partner Joseph Goldstein set out to learn why children born with a severe form of an inherited disease, familial hypercholesterolemia (FH), had huge LDL levels and heart attacks in childhood. Growing skin cells from patients in dishes, they found in 1973 that normal cells carry receptors for LDL on their surface. Think of LDL particles as delivery trucks and the receptors as loading docks: a dock grabs a truck, pulls it inside, unloads the cholesterol and then returns to the surface to catch another. Cells from children with severe FH had few or no working docks, so LDL piled up in their blood. People with the milder, far more common form have about half the normal number. The pair also found a feedback loop: when a cell has plenty of cholesterol, it makes fewer docks and less cholesterol of its own. The way their receptors cycle into and out of cells, called receptor-mediated endocytosis, turned out to be a general route by which cells take in many substances. It also explained how statin drugs work. By blocking the liver's own cholesterol production, statins push liver cells to build more docks, which pull more LDL out of the blood.[1],[3],[4],[9]

“The physician-scientist must be brave enough to adopt new methods.”
Michael S. Brown, From his banquet speech at the 1985 Nobel celebrations in Stockholm, on the qualities doctors need to make discoveries.[5]

What it meant for humanity

Brown and Goldstein used an inherited disease to explain a problem that touches almost everyone. The Nobel Assembly's announcement noted that heart attacks are a major cause of death in most industrialized countries, and that genes and diet together raise blood cholesterol by reducing the number of working LDL receptors. That gave medicine a clear target: raise the number of receptors in the liver and blood LDL falls. Statins do exactly that. Akira Endo in Japan isolated the first statin in 1973, and Merck's lovastatin became the first approved for patients in 1987. Brown and Goldstein showed in cells and in dogs how these drugs work, and Brown has said they helped Merck's scientists develop lovastatin. Large trials then proved the payoff. In 1994 the 4S study showed that simvastatin cut heart attacks and lengthened lives. Across 14 trials with more than 90,000 people, each 1 mmol/L drop in LDL cholesterol cut deaths from all causes by about 12% and heart attacks, strokes and artery-clearing procedures by about a fifth. By 2018 an estimated 173 million people in 83 countries used cholesterol-lowering drugs, and statins were the most used type. One US study credited lower average cholesterol levels, from all causes, with about a quarter of the drop in coronary deaths between 1980 and 2000. The receptor work also explained FH itself, which affects at least 1 in 500 people. Later, researchers found that a protein called PCSK9 destroys LDL receptors, and drugs that block it, first approved in the US in 2015, lower LDL further by protecting those receptors.

  • Their receptor discovery explained familial hypercholesterolemia, an inherited disorder that affects at least 1 in 500 people and, in its rare severe form, can cause heart attacks in childhood.[4],[9]
  • Statins lower LDL by pushing liver cells to make more LDL receptors, a mechanism Brown and Goldstein proposed in 1978 and tested in dogs in 1981 using Merck's mevinolin, later called lovastatin.[9],[10],[22]
  • In 14 statin trials with 90,056 people, each 1 mmol/L fall in LDL cholesterol cut deaths from all causes by 12% and major heart attacks, strokes and artery-clearing procedures by about a fifth.[11]
  • An estimated 173 million people in 83 countries used cholesterol-lowering drugs in 2018, and statins were the most used class.[13]
  • In the United States, lower average cholesterol levels, from all causes, accounted for about 24% of the fall in coronary heart disease deaths between 1980 and 2000.[15]

Impact in numbers

Brown's impact runs through the heart-disease prevention that statins made possible and through cell biology more broadly. We count one benefit and one harm from statin therapy since lovastatin's approval in 1987: roughly 1.7 to 4.8 million deaths prevented or postponed worldwide, and roughly 1.4 to 4.1 million extra diabetes diagnoses. Each is credited to Brown at 5%, the same as co-laureate Joseph Goldstein. The share is deliberately small. Akira Endo discovered the first statin, Merck and other companies developed the drugs, and large trials proved they save lives; Brown and Goldstein explained how statins lower LDL and, by Brown's account, helped Merck develop the first one. The count leaves out the far larger number of non-fatal heart attacks and strokes prevented, the benefit to families with FH, and newer drugs such as PCSK9 blockers that also act by raising LDL receptors. It also leaves out receptor-mediated endocytosis and the SREBP pathway, discoveries that changed how biologists understand the way cells take in molecules and sense cholesterol, and that cannot honestly be turned into a number.

HealthFundamental science

Each number is the laureate’s credited share of a real-world outcome, cumulative to 2025. The whole outcome, the share of credit, and the reasoning are shown so you can check the arithmetic. Outcomes shared with other laureates are counted once on the impact page.

  • Medium confidenceRippleModeledHealth

    Deaths prevented or postponed by statin therapy worldwide (1987-2025)

    85,000–240,000

    lives saved, credited share

    That is 5% of 1.7–4.8 million lives saved since 1987.

    How this number was built

    Range matches co-laureate Goldstein's profile. Users: Blais 2021 estimates 173M on lipid drugs in 2018; per-capita use rose ~50% from 2008, so ~110M then. Assume 85% statins (93% of US users in 2011-12): ~95M (2008), ~147M (2018). Person-years: 1987-2008 ramp from zero 0.7-1.0B (18% of US adults 40+ already took statins in 2003-04); 2008-18 1.2B; 2018-25 1.0-1.2B (flat to +4%/yr). Total 2.9-3.4B. Effect: in CTT 2005 trials (90,056 people, ~5 yrs) deaths ran 1.8%/yr and fell ~13% at a mean 1.09 mmol/L LDL cut, about 2.5 averted per 1,000 person-years; real-world use (lower risk, doses, adherence) 0.6-1.4. Result: 2.9B x 0.6 = 1.74M; 3.4B x 1.4 = 4.76M; rounded 1.7-4.8M. Share 0.05 (0.10 with Goldstein): Endo found the first statin, Merck developed it, trialists proved it saves lives; Brown and Goldstein explained how it works and aided lovastatin's development.[6],[9],[10],[11],[13],[14],[22]

    Sources: The Lancet (PubMed record); Atherosclerosis (PubMed record); US Centers for Disease Control and Prevention, National Center for Health Statistics; Proceedings of the Japan Academy (via PubMed Central); Cell (via PubMed Central); NobelPrize.org (Nobel Prize Outreach); Proceedings of the National Academy of Sciences (via PubMed Central)

  • HarmLow confidenceRippleModeledHealth

    Extra diabetes diagnoses caused by statin therapy worldwide (1987-2025)

    105,000–255,000

    people harmed, credited share

    That is 5% of 2.1–5.1 million people harmed since 1987.

    How this number was built

    Same 2.9-3.4B statin person-years (1987-2025) as the benefit claim (Blais). CTT 2024 individual-patient meta-analysis (19 placebo trials, 123,940 people): in people without diabetes, low/moderate-intensity statins added 1.2 new diagnoses per 1,000 person-years (RR 1.10, placebo 1.2%/yr); high-intensity raised diagnoses 36%, or 4.3 per 1,000 at that 1.2%/yr baseline. MEPS 2008-19: 20% of US statin use was high-intensity (less abroad and earlier, so 5-20%) and 18% of users already had diabetes, so 82% of person-years are at risk. Low: rates cut by a third for real-world dose and adherence, 5% high-intensity: (0.95 x 0.8 + 0.05 x 2.9) x 2.9B x 0.82 = 2.1M. High: (0.8 x 1.2 + 0.2 x 4.3) x 3.4B x 0.82 = 5.1M. CTT: about 62% of new diagnoses were in people already in the top quarter of baseline blood sugar. Share 0.05, matching the benefit claim and Goldstein.[13],[23],[24]

    Sources: The Lancet Diabetes & Endocrinology (PMC full text); Saudi Pharmaceutical Journal (PMC full text); Atherosclerosis (PubMed record)

The double edge

No misconduct by Brown is documented in the sources consulted, but the drugs his work helped bring into use have real side effects, and he has a commercial tie worth stating. An Oxford-led review of the trial evidence found that treating 10,000 people with an effective statin regimen for five years typically causes about 5 cases of myopathy, a form of muscle damage, 50 to 100 new diabetes diagnoses and 5 to 10 bleeding strokes, while preventing roughly 500 to 1,000 heart attacks, strokes and artery-clearing procedures. The same review found that most muscle aches blamed on statins are not caused by the drug, and warned that exaggerated claims about side effects may lead people to avoid or stop treatment they need. Brown recalled that in the first year after lovastatin reached the market, he feared every phone call would bring news of an unforeseen side effect. Separately, Brown and Goldstein have disclosed that they sit on the board of Regeneron Pharmaceuticals, where both have been directors since 1991, and own its shares. Regeneron sells alirocumab, a cholesterol drug that works by protecting LDL receptors.

  • Moderate

    Side effects of statin therapy

    Per 10,000 people treated for five years with an effective regimen, statins typically cause about 5 cases of myopathy (one of which could progress to rhabdomyolysis if the drug is not stopped), 50-100 new cases of diabetes and 5-10 haemorrhagic strokes. A 2010 analysis of 13 trials found one extra diabetes case per 255 people treated for four years. Both analyses judge these risks small next to the heart attacks and strokes prevented in people at raised risk.[12],[20]

  • Minor

    Financial ties to a cholesterol-drug maker

    Brown and Goldstein disclosed in 2015 that they are directors and shareholders of Regeneron Pharmaceuticals; Regeneron lists Brown as a director since 1991. Regeneron markets alirocumab (Praluent), a PCSK9 inhibitor approved in the US in 2015 that lowers LDL by increasing the number of LDL receptors. The tie is openly disclosed; no wrongdoing is alleged in the sources consulted.[9],[18],[19]

Against the odds

Brown faced no persecution, and his story is mostly one of opportunity. In the America of his youth, the main barrier for Jewish would-be doctors was the admissions quota. From the 1920s most US medical schools limited how many Jewish students they took, and the practice was well entrenched by 1945. Yale's medical school, for example, was to admit no more than five Jewish students per class. After the Second World War, investigations in New York and in Philadelphia, the city Brown grew up next to, exposed the quotas, and by 1970 they were gone. Brown studied at the University of Pennsylvania from 1958 and at its medical school from 1962, as these barriers were falling, and the sources consulted do not describe him meeting antisemitism. His hurdles were more ordinary. His father was a textile salesman, and Brown recalled that money was short during medical school, so he spent his summers doing routine lab work at a drug company to earn it, while friends who did not need the money took more exciting research jobs.

  • —

    Quota

    From the 1920s most US medical schools capped Jewish admissions, and the quotas were well entrenched by 1945. Investigations in New York and Philadelphia helped expose them, and they were gone by 1970. Brown entered medical school in 1962, while they were fading.[16],[17]

  • —

    Other

    Brown recalled that money was short during medical school, so he spent his summers earning it with a routine job in a Philadelphia drug company's laboratory rather than in research labs.[6]

Jewish background

One Jewish parentCulturally Jewish

Brown was born in Brooklyn in 1941 to Harvey Brown, a textile salesman, and Evelyn Brown, a homemaker. When he won the Nobel Prize in 1985, the Jewish Telegraphic Agency named him among three American Jewish scientists honored that year. It reported that he and his wife, Alice Lapin Brown, belonged to Shearith Israel, a Conservative synagogue in Dallas, where their daughters attended Hebrew school. The Encyclopaedia Judaica has an entry on him. No source consulted gives each parent's background or describes his personal religious practice.[2],[7],[8],[21]

Key dates

  1. April 13, 1941

    Born in Brooklyn, New York, the eldest child of Harvey Brown, a textile salesman, and Evelyn Brown, a homemaker.[1],[2]

  2. 1952

    At age 11, moves with his family to Elkins Park, a suburb of Philadelphia, where he later attends Cheltenham High School.[2]

  3. 1962

    Graduates from the University of Pennsylvania with a chemistry major, after years working on the student newspaper.[2]

  4. 1964

    Marries Alice Lapin, a childhood companion.[2]

  5. 1966

    Earns his MD at Penn and begins training at Massachusetts General Hospital in Boston, where he meets fellow intern Joseph Goldstein.[2]

  6. 1968

    Joins the National Institutes of Health, where he learns enzyme chemistry in Earl Stadtman's laboratory.[2],[5]

  7. 1971

    Moves to the University of Texas Southwestern Medical School in Dallas, drawn by Goldstein and department chairman Donald Seldin.[2],[6]

  8. 1972

    Begins formal collaboration with Goldstein on familial hypercholesterolemia.[2],[3]

  9. 1973

    With Goldstein, discovers the LDL receptor that takes cholesterol-carrying particles into cells.[1],[4]

  10. 1974

    Shows with Goldstein that familial hypercholesterolemia stems from inherited defects in the LDL receptor; their two labs formally merge.[2],[3],[9]

  11. 1981

    With Goldstein, shows in dogs that Merck's statin mevinolin (later lovastatin), given with a bile-acid binder, boosts liver LDL receptors and speeds LDL removal.[9],[10],[22]

  12. 1985

    Shares the Nobel Prize in Physiology or Medicine with Goldstein; the pair also receive the Lasker Award that year.[1],[2],[4]

  13. 1993

    His lab with Goldstein isolates SREBP, the switch that tells cells when to make or take up more cholesterol.[9]

Sources

  1. 1.Michael S. Brown - Facts · NobelPrize.org (Nobel Prize Outreach)
  2. 2.Michael S. Brown - Biographical (from Les Prix Nobel 1985) · NobelPrize.org (Nobel Foundation), 1985
  3. 3.A Receptor-Mediated Pathway for Cholesterol Homeostasis (Nobel Lecture by Michael S. Brown and Joseph L. Goldstein, December 1985) · NobelPrize.org (Nobel Foundation), 1985
  4. 4.The Nobel Prize in Physiology or Medicine 1985 - Press release · NobelPrize.org (Nobel Assembly at Karolinska Institutet), 1985
  5. 5.Michael S. Brown - Banquet speech · NobelPrize.org (Nobel Foundation), 1985
  6. 6.Michael S. Brown - Interview (with Adam Smith, UT Southwestern, April 2007) · NobelPrize.org (Nobel Prize Outreach), 2007
  7. 7.3 U.S. Jewish Scientists Awarded Nobel Prizes for 1985 · Jewish Telegraphic Agency, 1985
  8. 8.Jewish Nobel Prize Winners in Medicine · JINFO.org
  9. 9.A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins (Goldstein JL, Brown MS; Cell 161(1):161-172) · Cell (via PubMed Central), 2015
  10. 10.A historical perspective on the discovery of statins (Endo A; Proc Jpn Acad Ser B 86(5):484-493) · Proceedings of the Japan Academy (via PubMed Central), 2010
  11. 11.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins (Cholesterol Treatment Trialists' Collaborators; Lancet 366:1267-78) · The Lancet (PubMed record), 2005
  12. 12.Interpretation of the evidence for the efficacy and safety of statin therapy (Collins R et al.; Lancet 388:2532-61) · The Lancet (PubMed record), 2016
  13. 13.Trends in lipid-modifying agent use in 83 countries (Blais JE et al.; Atherosclerosis 328:44-51) · Atherosclerosis (PubMed record), 2021
  14. 14.Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003-2012 (NCHS Data Brief No. 177) · US Centers for Disease Control and Prevention, National Center for Health Statistics, 2014
  15. 15.Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 (Ford ES et al.; N Engl J Med 356:2388-98) · New England Journal of Medicine (PubMed record), 2007
  16. 16.Why Did the United States Medical School Admissions Quota for Jews End? (Halperin EC; Am J Med Sci 358(5):317-325) · American Journal of the Medical Sciences (PubMed record), 2019
  17. 17.Jewish American Heritage Month: The Forgotten History of Quotas in American Medical School Admissions · Himmelfarb Health Sciences Library, George Washington University, 2023
  18. 18.Leadership and Board of Directors · Regeneron Pharmaceuticals
  19. 19.PRALUENT (alirocumab) injection - US Prescribing Information · Regeneron Pharmaceuticals, 2025
  20. 20.Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (Sattar N et al.; Lancet 375:735-42) · The Lancet (PubMed record), 2010
  21. 21.Brown, Michael Stuart (Encyclopaedia Judaica, 2nd ed., entry by Ruth Rossing) · Encyclopaedia Judaica (via Encyclopedia.com), 2007
  22. 22.Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog (Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS; PNAS 78(2):1194-1198) · Proceedings of the National Academy of Sciences (via PubMed Central), 1981
  23. 23.Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis (Cholesterol Treatment Trialists' Collaboration) · The Lancet Diabetes & Endocrinology (PMC full text), 2024
  24. 24.Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC/AHA guidelines (MEPS 2008-2019) · Saudi Pharmaceutical Journal (PMC full text), 2023

Fact-checked on September 24, 2026 by a separate AI fact-checking pass that re-opened the sources, with 12 corrections made. How we check

Suggest a correction